The CCNYL1 (Cyclin Y-like 1) antibody is a research tool designed to detect and study the CCNYL1 protein, a member of the cyclin family. Cyclins are regulatory proteins that control cell cycle progression by interacting with cyclin-dependent kinases (CDKs). While cyclins like Cyclin D and Cyclin E are well-characterized, CCNYL1 remains less understood. It shares structural homology with Cyclin Y but exhibits distinct functional properties. CCNYL1 is implicated in cell cycle regulation, particularly in the G1/S phase transition, and may influence CDK activity. Recent studies suggest its involvement in diverse cellular processes, including DNA repair, transcriptional regulation, and signaling pathways such as Wnt/β-catenin. Aberrant CCNYL1 expression has been observed in certain cancers, linking it to tumorigenesis and disease progression. The antibody enables detection via techniques like Western blotting, immunohistochemistry, and immunofluorescence, aiding in exploring its spatial-temporal expression and mechanistic roles. Researchers utilize CCNYL1 antibodies to investigate its interaction partners, post-translational modifications, and potential as a therapeutic target. However, functional insights remain limited, necessitating further validation of its biological significance across different tissues and pathological contexts. Commercial CCNYL1 antibodies are typically developed in rabbit or mouse hosts, with validation data emphasizing specificity and cross-reactivity controls.